Table 3. Number of subjects in the intervention group displaying serum ALT above reference levels during the study and at follow-up.
| ALT reference levels | Baseline (men n = 12, women n = 6) | Week 1 (men n = 12, women n = 6) | Week 2 (men n = 12, women n = 6) | Week 3 (men n = 11, women n = 6) | Week 4 (men n = 11*, women n = 6) | Persistent elevation from week 1 to study end | Follow-up after 6 months (n = 17**) |
| Men >40 U/l† | 1 | 7 | 5 | 6 | 8 | 5 | 1 |
| Men >30 U/l†† | 2 | 9 | 11 | 10 | 10 | 8 | 3 |
| Women >31 U/l† | 0 | 2 | 3 | 3 | 2 | 1 | 0 |
| Women >19 U/l†† | 1 | 5 | 4 | 3 | 4 | 3 | 2 |